"Increase our full year revenue range to between $4.675 billion to $4.760 billion" and "updating our full year EPS outlook to $14.45 to $14.90 per share" (Executive VP, CFO & Treasurer Emerson). "Our ...

Jonathan J. Mazelsky, CEO, highlighted, "IDEXX delivered a very strong quarter of performance as reflected in solid execution across all key drivers of our strategy." He emphasized rapid adoption of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

IDEXX Laboratories (NASDAQ:IDXX) shares jumped on Monday after the company raised its full year revenue and profit guidance, banking on rising demand for its inVue Dx instrument placements. It lifted ...

AI-powered, load-and-go platform has potential to radically shift how veterinarians process, diagnose, and act on cytology and blood morphology cases The global launch of the IDEXX inVue Dx analyzer ...

The IDEXX inVue Dx analyzer, featuring a slide-free design, now includes FNA cytology starting with mast cell tumor detection for dogs. This diagnostic application allows veterinarians to evaluate ...

Detailed price information for Idexx Laboratories (IDXX-Q) from The Globe and Mail including charting and trades.

IDEXX Laboratories (NASDAQ:IDXX) executives reiterated the company’s long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product ...

IDEXX Laboratories (NASDAQ:IDXX) President and CEO Michael Erickson used a Stifel investor conference appearance to emphasize the company’s innovation pipeline, expanding commercial reach and growing ...

Cancer Dx expansion and inVue Dx FNA combine preventive screening and rapid, in-clinic diagnosis, enabling veterinarians and pet owners to act with confidence Mast Cell Tumors Are Common Mast cell ...